20,669 Shares in Danaher Corporation $DHR Bought by Benedict Financial Advisors Inc.

Benedict Financial Advisors Inc. acquired a new position in Danaher Corporation (NYSE:DHR) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 20,669 shares of the conglomerate’s stock, valued at approximately $4,579,000.

A number of other institutional investors also recently made changes to their positions in the business. Studio Investment Management LLC grew its holdings in Danaher by 3.3% during the second quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock valued at $302,000 after purchasing an additional 51 shares during the period. Clal Insurance Enterprises Holdings Ltd raised its holdings in Danaher by 71.6% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock worth $29,000 after purchasing an additional 53 shares during the period. JDH Wealth Management LLC boosted its position in shares of Danaher by 4.5% during the first quarter. JDH Wealth Management LLC now owns 1,264 shares of the conglomerate’s stock worth $240,000 after purchasing an additional 55 shares in the last quarter. OLD Second National Bank of Aurora boosted its position in shares of Danaher by 0.5% during the first quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock worth $2,297,000 after purchasing an additional 57 shares in the last quarter. Finally, Adelphi Trust Co grew its holdings in shares of Danaher by 2.5% in the 3rd quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate’s stock valued at $524,000 after buying an additional 57 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 1.3%

Shares of Danaher stock traded up $2.72 during trading on Wednesday, reaching $218.33. The stock had a trading volume of 1,605,398 shares, compared to its average volume of 4,447,346. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $153.48 billion, a price-to-earnings ratio of 38.73, a P/E/G ratio of 2.75 and a beta of 0.76. The stock has a fifty day moving average price of $210.01 and a two-hundred day moving average price of $194.05. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same period last year, the company earned $0.77 earnings per share. Danaher’s quarterly revenue was up 5.5% on a year-over-year basis. Sell-side analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is currently 28.42%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on DHR shares. Royal Bank Of Canada upped their price objective on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research report on Monday. UBS Group initiated coverage on Danaher in a research note on Wednesday, September 9th. They issued a “buy” rating and a $250.00 target price for the company. The Goldman Sachs Group increased their price target on Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Evercore reaffirmed an “outperform” rating and set a $230.00 price target on shares of Danaher in a research report on Monday, July 6th. Finally, Guggenheim lifted their price objective on Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $235.23.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.